GlobeNewswire Inc | Feb 9, 2021 08:00AM EST

February 09, 2021

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc.(Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is using its platform to genetically engineer red blood cells into medicines, called Red Cell Therapeutics, for the treatment of cancer and autoimmune diseases, today announced plans to report fourth quarter and full year 2020 financial results onTuesday, February 23, 2021, before market open.

The company will not be hosting a teleconference in conjunction with its financial results press release.

AboutRubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics. The Companys proprietary RED PLATFORM was designed to genetically engineer and culture Red Cell Therapeutics that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius initial focus is to advance RCT product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities potent cell-cell interaction and tolerance induction. Rubius Therapeutics manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:Elhan Webb, CFAVice President, Investor Relationselhan.webb@rubiustx.com

Media:Marissa HanifyDirector, Corporate Communicationsmarissa.hanify@rubiustx.com

Dan Budwick1AB +1 (973) 271-6085dan@1abmedia.com